Study of a new drug (KK8123) for adults with XLH
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH). It aims to see if KK8123 can safely raise low blood phosphorus levels. The trial includes two parts and may offer a new treatment option if you have not used burosumab recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of X-linked hypophosphatemia (XLH).
- You should be between 18 and 65 years old when you join the study.
- Your blood phosphorus level must be lower than 2.5 mg/dL (0.81 mmol/L) at the screening visit.
- You must not have used burosumab (Crysvita) in the last 7 months.
- You must not be taking certain other XLH medications (active vitamin D, oral phosphate, etc.) within 2 weeks before screening, unless you can safely stop them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
This study uses a special MRI scan to look at phosphorus levels in the muscles of people with phosphate diabetes (a condition where the body loses too much phosphate through the kidneys). It aims to better understand how this condition affects muscles and may help guide future treatments.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This study looks at how young people with X-linked hypophosphataemia (XLH) respond to different doses of burosumab. The goal is to find the best dose to manage the condition.
This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
Hear when a new X-linked Hypophosphatemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.